Discovery and characterization of UCB-1A: the first PET radioligand for imaging synaptic vesicle glycoprotein 2C

This study reports the discovery and characterization of UCB-1A as the first PET radioligand capable of selectively imaging the synaptic vesicle glycoprotein 2C (SV2C) in vivo, establishing it as a promising biomarker for the early diagnosis and progression assessment of Parkinson's disease.

The Gist

Imagine your brain is a bustling, high-tech city. In this city, there are millions of tiny delivery trucks (neurons) constantly shuttling packages (chemical signals) to keep everything running smoothly. One of the most important delivery hubs is the Basal Ganglia, a district responsible for coordinating movement.

For a long time, scientists knew that in Parkinson's disease, the delivery trucks in this district start breaking down, and the roads get clogged. But they had a problem: they could only see the trucks that were already gone. They couldn't see the damage to the roads or the delivery hubs themselves until it was too late. They needed a new kind of "traffic camera" to see the very first signs of trouble.

This paper introduces that new camera: a special glowing dye called [11C]UCB-1A.

Here is the story of how they built it and what it does, explained simply:

1. The Missing Piece of the Puzzle: SV2C

Inside the delivery hubs, there are specific "loading docks" called SV2C. These docks are crucial for regulating how much dopamine (the fuel for movement) gets loaded onto the trucks.

• The Problem: In Parkinson's, these SV2C docks get damaged or disappear, but standard brain scans can't see them.
• The Goal: The researchers wanted to build a key that fits only into the SV2C lock, so they could light it up and see exactly how many docks are left.

2. Finding the Perfect Key (UCB-1A)

The team started with a massive library of 180,000 different chemical "keys." They needed one that would:

• Fit perfectly into the SV2C lock.
• Ignore all the other similar locks (SV2A and SV2B) in the brain.
• Be small enough to enter the brain but strong enough to stick.

After testing thousands, they found a winner: UCB-1A. Think of it like finding a master key that opens only the front door of the delivery hub, ignoring all the side doors and windows. It was so precise that it ignored the other locks 100 times more than it tried to open them.

3. Testing the Key in the Lab (The "Toy City" Phase)

Before taking it to a real human, they tested it on "toy cities" (rat and monkey brains).

• The Map: They painted the brain slices with the glowing key. It lit up brightly in the areas known to control movement (the substantia nigra and striatum), exactly where the SV2C docks are supposed to be.
• The Damage Test: They created a "broken" toy city (rats with Parkinson's-like damage). When they used the key, the lights in the damaged areas were dimmer. This proved the key could actually see the disease.
• The Human Test: They looked at brain tissue from real people who had passed away with Parkinson's. The key showed that the "loading docks" were indeed fewer in the damaged parts of the brain compared to healthy people.

4. The Real-World Test (The "Live Traffic" Phase)

Now, they had to make the key glow in real-time. They attached a tiny, safe radioactive tag (Carbon-11) to the key, turning it into [11C]UCB-1A. This is like giving the key a flashlight so it can be seen from the outside of the skull.

They injected this glowing key into non-human primates (monkeys) and watched their brains with a PET scanner (a super-advanced camera).

• The Result: The camera saw the key travel to the brain, stick to the SV2C docks, and light up the movement centers.
• The Safety Check: They gave the monkeys other drugs to block the docks. When they blocked the SV2C docks, the glowing key couldn't stick, and the lights went out. This confirmed the key wasn't just sticking to random things; it was specifically finding SV2C.

5. Why This Changes Everything

Currently, doctors use PET scans to count how many delivery trucks are left. But by the time the trucks are gone, the disease has already progressed significantly.

[11C]UCB-1A is different. It looks at the loading docks (SV2C).

• Early Warning System: Because the docks get damaged before the trucks disappear, this new scan could potentially diagnose Parkinson's much earlier—perhaps even before the patient starts shaking or moving slowly.
• Tracking Progress: It could act like a ruler, allowing doctors to measure exactly how fast the disease is spreading and if new medicines are actually fixing the problem.

The Bottom Line

The researchers have successfully built the first-ever "flashlight" that can see the specific molecular damage happening in the brains of people with Parkinson's disease. While they still need to test it on humans to be sure, this discovery is like finding a new pair of glasses that lets us see the disease in its earliest, most treatable stages. It's a huge step toward catching Parkinson's before it catches us.

Technical Summary

1. Problem Statement

• Clinical Need: Parkinson's disease (PD) involves early synaptic dysfunction (synaptopathy) preceding neuronal loss. Current PET imaging markers for PD primarily target the dopaminergic system (e.g., dopamine transporters) or SV2A (via [11C]UCB-J). However, SV2A imaging has failed to show longitudinal changes suitable for monitoring disease progression.
• Target Gap: Synaptic Vesicle Glycoprotein 2C (SV2C) is a protein highly expressed in the basal ganglia (substantia nigra, striatum, globus pallidus) and is genetically linked to PD. Evidence suggests SV2C regulates dopamine release and is altered in PD models and human post-mortem tissue.
• Objective: To discover, characterize, and validate a novel Positron Emission Tomography (PET) radioligand capable of imaging SV2C in vivo to serve as a biomarker for early PD diagnosis and progression monitoring.

2. Methodology

The study employed a translational approach combining in silico, in vitro, and in vivo techniques:

• Compound Discovery & Selection:
  • Screened a library of ~180,000 compounds from UCB BioPharma.
  • Selected UCB-1A based on high affinity for human SV2C (pIC50 ~7.4), >100-fold selectivity over SV2A and SV2B, favorable physicochemical properties (logP < 2, logD < 3), and feasibility for radiolabeling.
• In Silico Modeling:
  • Molecular dynamics simulations (100 ns) were performed to analyze the binding pose of UCB-1A to SV2A and SV2C at 4°C and 37°C.
• Radiolabeling:
  • Developed a synthesis route for [11C]UCB-1A using [11C]methyltriflate and a precursor (UCB-1).
  • Also prepared [3H]UCB-1A for in vitro autoradiography and saturation binding.
• In Vitro Characterization:
  • Saturation Binding: Measured $K_D$ and $B_{max}$ on recombinant proteins and rat/NHP brain homogenates.
  • Autoradiography: Performed on rat, non-human primate (NHP), and human post-mortem brain sections to map distribution and test specificity using blockers (UCB-1A, UCB-7, Levetiracetam, Seletracetam, UCB5203).
  • Disease Models: Tested binding in 6-hydroxydopamine (6-OHDA) lesioned rats (PD model) and post-mortem brain tissue from PD donors vs. controls.
• In Vivo PET Studies (NHPs):
  • Conducted 14 PET scans in four cynomolgus monkeys.
  • Evaluated pharmacokinetics, brain uptake, and metabolism (radiometabolite analysis via HPLC).
  • Quantification: Used 1-Tissue Compartment Model (1-TCM), 2-TCM, Logan graphical analysis, and MA1 to calculate Volume of Distribution ($V_T$).
  • Blocking Studies: Administered Levetiracetam (SV2A blocker), UCB-1A (SV2C blocker), Seletracetam (SV2A), and UCB5203 (SV2B) to determine in vivo selectivity and occupancy.

3. Key Contributions

• First-in-Class Radioligand: UCB-1A is the first PET radioligand specifically developed for imaging SV2C.
• High Selectivity: Demonstrated >100-fold selectivity for SV2C over SV2A and SV2B in vitro.
• Translational Validation: Successfully bridged findings from recombinant proteins to rat models, NHPs, and human post-mortem tissue.
• Disease Correlation: Provided the first evidence linking SV2C availability changes to PD pathology in both animal models and human tissue.

4. Key Results

A. Binding Properties & Selectivity

• Affinity: $K_D$ for SV2C ranged from 6 to 15 nM across species (human, NHP, mouse, rat).
• Selectivity: $K_D$ for SV2A and SV2B was ~400 nM and ~800 nM, respectively, confirming >100-fold selectivity.
• In Silico: UCB-1A binds to a conserved pocket in SV2 proteins, anchored by $\pi$-$\pi$ contacts and hydrogen bonds. Stability was higher for SV2C at 37°C compared to SV2A.

B. Distribution Patterns

• High Density Regions: Highest binding observed in the globus pallidus, substantia nigra, brainstem nuclei, and striatum (consistent with SV2C expression).
• Low Density Regions: Lowest binding in the cortex and cerebellum.
• Specificity: Binding was completely blocked by unlabeled UCB-1A and significantly reduced by UCB-7. Levetiracetam (SV2A) showed minimal blocking, while SV2A/SV2B selective blockers had no effect.

C. Disease Models (6-OHDA Rats & Human PD)

• 6-OHDA Rats: Specific binding of [3H]UCB-1A was reduced (~21–31%) in the lesioned striatum. Conversely, binding was increased (~22–42%) in the substantia nigra of the lesioned side, suggesting a compensatory upregulation of SV2C in remaining neurons.
• Human PD Post-Mortem:
  • Striatum/Putamen: Significant reduction in binding (12–30% lower) in PD donors compared to controls.
  • Globus Pallidus: Significant increase in binding (26–34% higher) in PD donors.
  • Ratio: The ratio of Globus Pallidus/Putamen binding was significantly higher in PD donors (2.51) vs. controls (1.25), offering a potential diagnostic metric.

D. In Vivo PET in NHPs

• Pharmacokinetics: [11C]UCB-1A showed high brain uptake, reversible kinetics, and moderate metabolism (28% unchanged in plasma at 60 min). Metabolites were polar and likely did not enter the brain.
• Quantification: The 2-TCM was the preferred model. $V_T$ values mirrored in vitro distribution (highest in GP and SN).
• Occupancy:
  • UCB-1A (1 mg/kg): Caused ~92% occupancy in high-density regions, confirming specific SV2C binding.
  • Levetiracetam (10–30 mg/kg): Caused only ~10–18% occupancy, confirming that SV2A contributes minimally to the signal in high-density regions.
  • Selectivity Calculation: Estimated that ~80–85% of the specific binding in high-density regions is attributable to SV2C.

5. Significance and Future Implications

• Biomarker Potential: [11C]UCB-1A represents a breakthrough tool for visualizing synaptic integrity specifically in the basal ganglia, a region critical for motor control and heavily affected in PD.
• Early Diagnosis: The ability to detect SV2C changes (reduction in striatum, compensatory increase in pallidum/SN) suggests this ligand could detect synaptopathy before massive neuronal death occurs.
• Disease Monitoring: The distinct binding patterns in PD models and human tissue indicate potential for monitoring disease progression and evaluating therapeutic efficacy.
• Broader Applications: Given the distribution in motor pathways, this ligand may also be useful for studying other neurodegenerative disorders like Amyotrophic Lateral Sclerosis (ALS).
• Next Steps: The authors plan First-in-Human (FiH) studies to validate these findings in living patients, noting that arterial blood sampling will likely be required for quantification due to the lack of a perfect reference region (cerebellum shows some specific binding).

Conclusion: The study successfully identifies and validates [11C]UCB-1A as a highly selective, high-affinity PET radioligand for SV2C, offering a promising new avenue for the molecular imaging of Parkinson's disease pathology.